RGBP (Regen BioPharma) 1-Year Share Buyback Ratio: -1,530.40% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regen BioPharma 1-Year Share Buyback Ratio?

Regen BioPharma RGBP +33.33% 1-Year Share Buyback Ratio is -1,530.40 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,116 Biotechnology companies, Regen BioPharma ranks worse than 97.49% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Regen BioPharma's current 1-Year Share Buyback Ratio was -1,530.40%.

RGBP's 1-Year Share Buyback Ratio is ranked worse than
97.49% of 1116 companies
in the Biotechnology industry
Industry Median: -13.25 vs RGBP: -1530.40

Regen BioPharma  (OTCPK:RGBP) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Regen BioPharma 1-Year Share Buyback Ratio Related Terms

RGBP vs IOBTQ, SCPX, LIPO: 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Regen BioPharma's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's 1-Year Share Buyback Ratio falls into.


Regen BioPharma 1-Year Share Buyback Ratio Calculation

Regen BioPharma's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(21.555 - 351.439) / 21.555
=-1,530.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -1,530.40 mean?
Regen BioPharma (RGBP) has a 1-Year Share Buyback Ratio of -1,530.40 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #1088 out of 1116 companies in the Biotechnology industry, placing it in the top 97.5%.
Is Regen BioPharma's 1-Year Share Buyback Ratio too high?
Regen BioPharma's current 1-Year Share Buyback Ratio is -1,530.40. Based on the distribution chart, Regen BioPharma ranks #1088 out of 1116 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's 1-Year Share Buyback Ratio compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #1088 out of 1116 companies for 1-Year Share Buyback Ratio. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Regen BioPharma and its competitors. Regen BioPharma's current 1-Year Share Buyback Ratio is -1,530.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current 1-Year Share Buyback Ratio is -1,530.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 1-Year Share Buyback Ratio is -1,530.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.